Login to Your Account



CV heebie-jeebies: Zetia vote by FDA panel jolting; path even Merck-ier now

By Randy Osborne
Staff Writer

Tuesday, December 15, 2015

The 10-5 vote by the FDA's EMDAC against expanding the label for Merck & Co. Inc.'s cholesterol-lowering drug Zetia to include CV benefit surprised analysts and likely gave the jimjams to developers across the space.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription